Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-04-24
2011-12-06
Pak, Michael (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
Reexamination Certificate
active
08071287
ABSTRACT:
A pharmaceutical composition comprising an expression product of a Type Nine adenylyl cyclase gene polymorphism, along with a suitable physiological carrier, are provided. In addition, methods related to treating patients having asthma or a reversible bronchial obstruction, kits for determining the responsiveness of an individual to treatment regimens, and assays for screening pharmaceutical for efficacy in treatment are also provided.
REFERENCES:
patent: 5541308 (1996-07-01), Hogan et al.
patent: 2001/0041718 (2001-11-01), Thompson et al.
patent: 2002/0142436 (2002-10-01), Antoni et al.
Nelson et al, “Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma,” J. Allergy Clin. Immunol., vol. 107, No. 2, pp. 398-416. Feb. 2000.
Small et al, “An Ile Met polymorphism in the catalytic domain of adenylyl cyclase type 9 confers reduced Beta-2-adrenergic receptor stimulation,” Pharmacogenetics 2003, vol. 13, No. 9, pp. 535-541.
Drysdale et al, “Complex promoter and coding region Beta-2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness,” PNAS, Sep. 12, 2000, vol. 97, No. 19, pp. 10483-10488.
Aksoy et al., “Glucocorticoid effects on the β-adrenergic receptor-adenylyl cyclase system of human airway epithelium,” J. Allergy Clin. Immunol., Mar. 2002, vol. 109, No. 3, pp. 492-497.
Drazen et al., “Heterogeneity of therapeutic responses in asthma,” British Medical Bulletin, 2000, vol. 56, No. 4, pp. 1054-1070.
Israel et al., “Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial,” www.thelancet.com., Oct. 23, 2004, vol. 364, pp. 1505-1512.
Lima et al., “Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics,” Clinical Pharmacology & Therapeutics, May 1999, vol. 65, No. 5, pp. 519-525.
Mialet-Perez et al., “A primate-dominant third glycosylation site of the β2-adrenergic receptor routes receptors to degradation during agonist regulation,” The Journal of Biological Chemistry, Sep. 10, 2004, vol. 279, No. 37, pp. 38603-38607.
Silverman et al., “Family-based association analysis of β2-adrenergic receptor polymorphisms in the childhood asthma management program,” J. Allergy Clin. Immunol., Nov. 2003, vol. 112, No. 5, pp. 870-876.
Drysdale C.M., et al., Proceedings the National Academy of Sciences, USA, Sep. 12, 2000, vol. 97, No. 19, pp. 10483-10488.
“Long-Term Effects of Budesonide or Nedocromil in Children With Asthma,” The New England Journal of Medicine, vol. 343, Oct. 12, 2000, No. 15.
“B1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure,” Perez, J.M., et al., Nature Medicine, vol. 9, No. 10, Oct. 2003, pp. 1300-1305.
Genetics of Asthma, Marcel Dekker, Inc., New York, pp. 91-117 (1996).
Dinsmore & Shohl LLP
Pak Michael
LandOfFree
Pharmaceutical and therapeutic applications relating to a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical and therapeutic applications relating to a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical and therapeutic applications relating to a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4303019